News | March 13, 2024
Nirma acquires majority stake in Glenmark Life Sciences
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The CDCCs are strategically positioned in regions identified as high-impact areas
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
European operations' revenue grew 58.4% to Rs 599.7 crore
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)